Landcadia Holdings IV, Inc. (LCA)

RESEARCH TRIANGLE PARK, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and other ophthalmic disorders, announced today that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to OPGx-LCA5, its investigational gene therapy for the treatment of Leber Congenital Amaurosis (LCA) due to genetic variations in the LCA5 gene.

Improvements in subjective and objective measures of efficacy observed at six months persisted for one year in patients with severe vision impairment from inherited retinal degeneration due to mutations in the LCA5 gene

First pediatric patient shows encouraging early safety profile and meaningful improvement in visual function at one month A second pediatric patient was recently dosed, and the pediatric cohort is expected to complete enrollment in Q2 2025; initial data from all three patients anticipated in Q3 2025 FDA Type D meeting provided clarity on next steps for a registrational trial design to support BLA submission, with potential trial initiation in 2026 DURHAM, N.C., April 08, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and to treat other ophthalmic disorders (“Opus” or the “Company”), today announced one-month clinical data from the first pediatric patient treated with its investigational gene therapy, OPGx-LCA5, in a Phase 1/2 open-label trial for LCA5-related inherited retinal disease (IRD).

New Data from First Three Adult Patients in Phase 1/2 Trial with OPGx-LCA5 Showed that Subjective and Objective Signs of Efficacy Persisted for One Year New Data from First Three Adult Patients in Phase 1/2 Trial with OPGx-LCA5 Showed that Subjective and Objective Signs of Efficacy Persisted for One Year

First patient dosed in the pediatric cohort of the Phase 1/2 trial of OPGx-LCA5; initial data on the cohort anticipated by Q3 2025 New 12-month data on the first three adult OPGx-LCA5 patients to be presented at a major medical conference in Q2 2025 FDA meeting scheduled in March 2025 to discuss Phase 3 trial design and registrational endpoints for OPGx-LCA5

EL SEGUNDO, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) --   With a mission to positively impact human health, climate change, constraints on natural resources and animal welfare, Beyond Meat, Inc. (NASDAQ: BYND), a leader in plant-based meat, today released its 2023 ESG Report and announced its Beyond Steak life cycle assessment (LCA) study.

BEIJING, July 3, 2023 /PRNewswire/ — Segway-Ninebot, a global enterprise in the field of intelligent short-distance transportation and service robots, has received the world’s first Life Cycle Assessment (LCA) Verification Statement for the electric scooter category from TÜV SÜD, a leading global testing and certification organization founded in 1866. This covers micromobility products of Ninebot Max […]...

SEOUL, South Korea and LOS ANGELES, Aug. 14, 2022 /PRNewswire/ – A new, five-month undercover investigation by Los Angeles-based Last Chance for Animals (LCA) and Seoul-based Animal Liberation Wave (ALW) has revealed stunning atrocities resulting from South Korea’s continued dog meat trade. LCA’s and ALW’s investigation, which concluded in June 2022, focused on South Korea’s […]...

A recent study by The Energy and Resources Institute (TERI), a first-of-its-kind in India, comparing the most used beverage packaging substrates, sh...

Landcadia Holdings III, Inc. (LCY) CEO Doug Cahill on Q1 2021 Results - Earnings Call Transcript

NEW YORK, Feb. 5, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is...

Concerns over delays in the merger vote were overblown. With that out of the way, let's look to the future of LCA and GNOG stock.

LCA stock keeps climbing in anticpation of a reverse merger that will fold Landcadia Holdings II into Golden Nugget Online Gaming. The post Landcadia Holdings II Stock Is Looking Like a Golden Nugget appeared first on InvestorPlace.

This was the year of the special purpose acquisition company, with many realizing excellent gains.

LCA stock has more than doubled since the merger with GNOG was announced. But eroding market share in New Jersey adds to questions elsewhere.

With the shareholder vote soon to be in the rearview mirror, owners of LCA stock will be able to focus on the emerging U.S. gambling market. The post Hold Landcadia Holdings II Stock Through This Time of Transition appeared first on InvestorPlace.